Skin Cancer Clinical Trials 2023

Browse 100 Skin Cancer Medical Studies Across 356 Cities

4 Phase 3 Trial · 1600 Skin Cancer Clinics

Clinical TrialsSkin Cancer Clinical Trials 2023
Reviewed by Michael Gill, B. Sc.
10 Skin Cancer Clinical Trials Near Me
Top Hospitals for Skin Cancer Clinical Trials
Image of M D Anderson Cancer Center in Texas.
M D Anderson Cancer Center
Houston
16Active Trials
31All Time Trials for Skin Cancer
1999First Skin Cancer Trial
Image of University of Alabama at Birmingham Cancer Center in Alabama.
University of Alabama at Birmingham Cancer Center
Birmingham
10Active Trials
14All Time Trials for Skin Cancer
2000First Skin Cancer Trial
Image of Penrose-Saint Francis Healthcare in Colorado.
Penrose-Saint Francis Healthcare
Colorado Springs
9Active Trials
13All Time Trials for Skin Cancer
2005First Skin Cancer Trial
Image of Porter Adventist Hospital in Colorado.
Porter Adventist Hospital
Denver
9Active Trials
13All Time Trials for Skin Cancer
2005First Skin Cancer Trial
Image of Northwestern University in Illinois.
Northwestern University
Chicago
9Active Trials
21All Time Trials for Skin Cancer
1999First Skin Cancer Trial
Top Cities for Skin Cancer Clinical Trials
Image of Denver in Colorado.
Denver
57Active Trials
Porter Adventist HospitalTop Active Site
Image of Anchorage in Alaska.
Anchorage
51Active Trials
Providence Alaska Medical CenterTop Active Site
Skin Cancer Clinical Trials by Phase of Trial
N/A Skin Cancer Clinical Trials
7Active Skin Cancer Clinical Trials
7Number of Unique Treatments
8Number of Active Locations
Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadorscetuximabVignetteIpilimumabStand-alone PortalDermatoscopeTreatment
Skin Cancer Clinical Trials by Age Group
< 65 Skin Cancer Clinical Trials
2Active Skin Cancer Clinical Trials
Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadorsGemcitabine
Most Recent Skin Cancer Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
30% Ascorbic Acid in DMSO for Non-melanoma Skin Cancer
6/12/2023
Phase < 1
Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors for Skin Cancer
6/3/2023
N/A
Stand-alone Portal for Cancer
1/1/2023
N/A
aminolevulinic acid hydrochloride gel, 10% for Skin Cancer
5/15/2022
Phase 4
Encorafenib for Melanoma
12/27/2021
Phase 2
Top Treatments for Skin Cancer Clinical Trials
Treatment Name
Active Skin Cancer Clinical Trials
All Time Trials for Skin Cancer
First Recorded Skin Cancer Trial
Pembrolizumab
9
33
2015
Ipilimumab
8
31
2010
Pharmacological Study
3
14
2005
Treatment
3
3
2004
Atezolizumab
3
6
2017
Recently Completed Studies with FDA Approved Treatments for Skin Cancer
Treatment
Year
Sponsor
IFx-Hu2.0
2021
Morphogenesis, Inc.
2141 V-11
2020
Rockefeller University
Injection of TVEC into target lesions - week 1-2
2018
University of Arizona
Aspirin
2018
University of California, San Francisco
Relatlimab
2016
M.D. Anderson Cancer Center
Pembrolizumab
2015
M.D. Anderson Cancer Center
CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
2015
M.D. Anderson Cancer Center

What Are Skin Cancer Clinical Trials?

Skin cancer is widespread because of the body's abnormal growth of skin cells. Most often, it develops in the skin that is exposed to the sun. However, it can also develop in areas that are not exposed to the sun. These studies are designed to evaluate new treatments for skin cancer.

Researchers assess the effectiveness of new medications, pharmacological combinations, surgical procedures, or adjustments to current treatment protocols. Clinical trials for skin cancer participants can give them access to new medicines before its released to the public. Researchers worldwide try to find new drugs and treatments for skin cancer and hope to see a cure one day.

Why Is Skin Cancer Being Studied Through Clinical Trials?

It is estimated that 1 in every five people in the United States develops skin cancer. Skin cancer can begin with a waxy bump on your skin, a flat brown lesion, or a bleeding sore that heals and keeps returning. When you see any of these marks on your skin, it's best to see a doctor. Skin cancer can lead to severe problems, and it's essential to find help.

What Are The Types Of Treatments Available For Skin Cancer?

Education + Action Plan - In this clinical trial, they will examine a clinical trial that uses a factorial experiment to analyze the individual and combined effects of an intervention component intended to improve the lives of skin cancer patients.

Young Tumor Infiltrating Lymphocytes - This trial will study whether an experimental skin cancer drug will be more effective than the current treatments. It will involve cell therapy, and they will compare the treatment to a patient who has had chemotherapy and patients who haven't.

What Are Some Recent Breakthrough Clinical Trials For Skin Cancer?

2016 - Ultraviolet Radiation Exposure - In this clinical trial, they studied the effects ultraviolet exposure has on skin cancer. They found that most skin cancer cases are preventable, and the survivors of other cancers are prone to developing skin cancer. They are at higher risk than ordinary people.

2013 - Skin cancer: a growing health problem for children - Skin cancer is beginning to become a problem for children, and they studied the causes of it in this clinical trial. They found that the increase is initiated in childhood, and melanoma is rising in children.

Who Are Some Of The Key Researchers Conducting Skin Cancer Clinical Trial Research?

Dr. Steven R. Feldman, MD, Ph.D.

Doctor Steven R. Feldman is a specialist in psoriasis treatments. He is a director of the Center for Dermatology Research. In addition, he completed his fellowship in 1991 at the Medical University of South Carolina Medical Center. Doctor Feldman also completed his Ph.D. at Duke University.

Dr. Phillip M. Williford, MD

Doctor Phillip M. Williford holds an MD certificate as a Dermatologic Surgeon. He got his medical degree from the great University of North Carolina at the Chapel Hill School of Medicine. He has been practicing for 20 years and is an excellent dermatologist.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: August 19th, 2023

References1 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. https://pubmed.ncbi.nlm.nih.gov/190977742 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30. https://pubmed.ncbi.nlm.nih.gov/260282553 Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Erratum In: Lancet Oncol. 2019 May;20(5):e242. https://pubmed.ncbi.nlm.nih.gov/282718694 Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242. https://pubmed.ncbi.nlm.nih.gov/282718695 Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242. https://pubmed.ncbi.nlm.nih.gov/282718696 Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954. https://pubmed.ncbi.nlm.nih.gov/254285057 Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul;17(7):2105-16. Review. https://pubmed.ncbi.nlm.nih.gov/105612658 Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul;17(7):2105-16. doi: 10.1200/JCO.1999.17.7.2105. https://pubmed.ncbi.nlm.nih.gov/105612659 Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008 Nov 10;26(32):5233-9. doi: 10.1200/JCO.2008.16.5449. Epub 2008 Sep 22. https://pubmed.ncbi.nlm.nih.gov/1880961310 Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014 Aug 12;349:g4829. doi: 10.1136/bmj.g4829. https://pubmed.ncbi.nlm.nih.gov/25116268
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top